featured
Midostaurin Plus Chemotherapy for FTL3 Mutated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation
N. Engl. J. Med 2017 Jun 23;[EPub Ahead of Print], RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, CD Bloomfield, C Thiede, TW Prior, K Döhner, G Marcucci, F Lo-Coco, RB Klisovic, A Wei, J Sierra, MA Sanz, JM Brandwein, T de Witte, D Niederwieser, FR Appelbaum, BC Medeiros, MS Tallman, J Krauter, RF Schlenk, A Ganser, H Serve, G Ehninger, S Amadori, RA Larson, H DöhnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.